2013-10-03 13:48:42 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Tekmira Pharmaceuticals Corporation (TKM) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Tekmira Pharmaceuticals Corporation (TKM). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Tekmira Pharmaceuticals Corporation investor.
Report Summary: Tekmira Pharmaceuticals Corporation is an above average quality company with a neutral outlook. Tekmira Pharmaceuticals Corporation has weak business growth and is run by first class management. The trend in Tekmira Pharmaceuticals Corporation fair value exchange rate against its closest rated-competitor, Helix Biopharma Corp., has been appreciating over the past 2 weeks. When compared to its closest competitor, Tekmira Pharmaceuticals Corporation shows similar overvaluation and is equally likely to outperform the market.
The report breaks down the Total StockMark into
its three components - business, management and price, performing an in-depth analysis of Tekmira Pharmaceuticals Corporation for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.